March 4th 2025
Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.
ADHD medications do not significantly increase cardiovascular disease risk
January 16th 2023A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
Prenatal benzodiazepine exposure not directly associated with ASD and ADHD
January 11th 2023A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.
Drug Holidays and Challenges in Treatment Adherence in Pediatric ADHD
December 13th 2022Robert L. Findling, MD, MBA, and Timothy Wilens, MD, consider the dosing and adherence challenges that arise in pediatric ADHD, as well as the potential benefits and damages of patients taking a break from treatment.
Does stimulant medication for pediatric ADHD affect adult height?
November 8th 2022A recent review found that multiple clinical trials indicated a reduction in adult height potential for children with long-term use of stimulant medication for treatment of ADHD, but other studies conflict with this data.